MannKind Corp share price logo

MannKind Corp

NASDAQ: MNKD

Small Cap

$3.58

+0.19

(+5.60%)

as on

MannKind Corp Stock Performance

as on June 10, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $3.41
    $3.60
    downward going graph

    4.75%

    Downside

    0.56%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.23
    $6.51
    downward going graph

    37.71%

    Downside

    81.84%

    Upside

    downward going graph

MannKind Corp share price movements today

Previous Close
$3.39
Open
$3.49
Volume
4.5M
Day's Low - High
$3.41 - $3.60
52 Week Low - High
$2.23 - $6.51

MannKind Corp Historical Returns

1 Month Return
-3.69 %
3 Month Return
+ 26.49 %
1 Year Return
-22.43 %
3 Year Return
-15.88 %
5 Year Return
-16.91 %

MannKind Corp Stock Fundamentals & Key Indicators

Check MannKind Corp market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.1B

EPS (TTM)

0.085

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.35%

PE Ratio (TTM)

0

PEG Ratio

4.3866

EBITDA

35.3M

Revenue (TTM)

360.8M

Profit Margin

-6.63%

Return On Equity TTM

0.00%

MannKind Corp vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of MannKind Corp with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
MannKind Corp image
MannKind Corp
BUY$1.1B-16.91%NA-6.63%NA
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$40.5B85.6%76.3312.55%NA
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$113.4B107.42%26.5235.51%NA
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$66.6B17.15%15.529.65%0.5700000000000001%

Stock Returns calculator for MannKind Corp Stock including INR - Dollar returns

The MannKind Corp stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

MannKind Corp investment value today

Current value as on today

₹91,169

Returns

-₹8,831

(-8.83%)

Returns from MannKind Corp Stock

-₹18,078 (-18.08%)

Dollar Impact

₹9,247 (+9.25%)

Analyst Recommendation on MannKind Corp Stock

Based on 12 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for MannKind Corp. Average target price of $7.59

MannKind Corp Share Price Target

Get share price movements and forecasts by analysts on MannKind Corp.

What analysts predicted

52.83%UPSIDE

Target Price

$7.59

Current Price

$3.58

Analyzed by

12 Analysts

Target

$7.59

MannKind Corp target price $7.59, a slight upside of 52.83% compared to current price of $3.58. According to 12 analysts rating.

Indian Investors' Interest in MannKind Corp Stock

Search interest for MannKind Corp Stock has increased by 98% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:98% versus previous 30 day period

MannKind Corp Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
58
66
72
70
76
78
76
82
111
90
Gross Profit
40
47
52
52
57
60
55
61
87
68
Operating Income
7
16
16
12
26
22
5
18
-7
-2
EBITDA
9
21
13
23
18
26
9
17
-2
3
Interest Expense
5
9
12
8
7
10
6
7
13
12
Depreciation
1
1
2
2
2
2
2
2
4
6
Income Before Tax
2
10
-1
12
8
13
0
7
-20
-16
Income Tax Expense
1
0
0
1
1
0
0
0
-4
0
Net Income
1
10
-2
11
7
13
0
7
-15
-16
Net Profit Margin
2.40%
16.04%
-2.78%
16.48%
9.67%
16.79%
0.87%
9.72%
-14.25%
-18.43%

MannKind Corp Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
174
11
27
63
65
75
99
198
285
348
Gross Profit
124
-5
7
35
40
36
42
136
208
287
Operating Income
67
-108
-76
-44
-47
-47
-64
8
72
38
EBITDA
64
-102
-75
-38
-44
-61
-56
15
77
27
Interest Expense
18
13
9
10
9
16
24
25
37
13
Depreciation
-
3
2
2
3
5
9
8
9
12
Income Before Tax
125
-117
-86
-51
-57
-80
-87
-10
30
1
Income Tax Expense
13
0
0
7
0
10
24
1
2
-4
Net Income
125
-117
-86
-51
-57
-80
-87
-11
27
5
Net Profit Margin
71.91%
-999.00%
-312.20%
-82.34%
-87.87%
-107.27%
-87.60%
-6.00%
9.66%
1.68%

MannKind Corp Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
10
-2
11
7
13
0
7
-15
-16
Operating Cash Flow
6
3
9
22
-6
8
23
-7
-5
Investing Cash Flow
-48
-55
-41
48
5
6
-25
-291
18
Financing Cash Flow
-3
-44
-2
-86
1
-5
71
247
-35
Change in Cash
-45
-95
-34
-16
0
9
70
-52
-22

MannKind Corp Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-117
-86
-51
-57
-80
-87
-11
27
5
Operating Cash Flow
-64
-37
-88
-28
-61
-80
34
42
18
Investing Cash Flow
16
0
-22
15
-151
4
-1
-96
-304
Financing Cash Flow
73
61
69
49
270
21
136
-137
315
Change in Cash
25
23
-41
36
57
-54
168
-191
28

Global Institutional Holdings in MannKind Corp

Funds
Holdings
The Goldman Sachs Group Inc
0.95%
Two Sigma Investments LLC
0.94%
Northern Trust Corp
0.87%
Vanguard Group Inc
5.79%
UBS Group AG
2.67%
See all

MannKind Corp News & Key Events

  • img

    Today's Timeline - 08 June

    Mon, 08:49 PM

    -

    MannKind's inhaled insulin, Afrezza, received FDA approval for children, showing positive data at ADA 2026.

    Mon, 09:04 PM

    -

    Jim Cramer highlights MannKind as a speculation stock on Mad Money, emphasizing its speculative nature.

Insights on MannKind Corp

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, MNKD has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, MNKD stock has moved up by 29.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. Common Stock has given 16.8% return, outperforming this stock by 30.3%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 3 quarters, 7.98M → -16.61M (in $), with an average decrease of 152.0% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 111.95M → 90.17M (in $), with an average decrease of 19.5% per quarter

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
OrganisationMannKind Corp
Headquarters1 Casper Street, Danbury, CT, United States, 06810
IndustryBiotechnology
CEODr. Michael E. Castagna Pharm.D.
E-voting on sharesClick here to vote

Key Management of MannKind Corp

Name

Title

Mr. Dominic Marasco R.Ph.

President of Endocrine Business Unit

Mr. Sanjay Singh M.B.A.

Executive Vice President of Technical Operations

Dr. Ajay Ahuja M.B.A., M.D.

Executive VP & Chief Medical Officer

Dr. Michael E. Castagna Pharm.D.

CEO & Director

Mr. Christopher B. Prentiss M.B.A.

Chief Financial Officer

Dr. David B. Thomson J.D., Ph.D.

Executive VP, General Counsel & Secretary

Dr. Stuart A. Tross Ph.D.

Chief People & Workplace Officer

FAQs

What is MannKind Corp share price today?

MannKind Corp share price today is $3.58 as on at the close of the market. MannKind Corp share today touched a day high of $3.6 and a low of $3.41.

What is the 52 week high and 52 week low for MannKind Corp share?

MannKind Corp share touched a 52 week high of $6.51 on and a 52 week low of $2.23 on . MannKind Corp stock price today i.e. is closed at $3.58,which is 45.01% down from its 52 week high and 60.54% up from its 52 week low.

What is MannKind Corp's market capitalisation today?

MannKind Corp market capitalisation is $0.00T as on .

How to invest in MannKind Corp Stock (MNKD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for MannKind Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in MannKind Corp Shares that will get you 0.4190 shares as per MannKind Corp share price of $3.58 per share as on June 10, 2026 at 1:29 am IST.

What is the minimum amount required to buy MannKind Corp Stock (MNKD) from India?

Indian investors can start investing in MannKind Corp (MNKD) shares with as little as ₹95.34 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.40 in MannKind Corp stock (as per the Rupee-Dollar exchange rate as on ). Based on MannKind Corp share’s latest price of $3.58 as on June 10, 2026 at 1:29 am IST, you will get 2.7933 shares of MannKind Corp. Learn more about fractional shares .

What are the returns that MannKind Corp has given to Indian investors in the last 5 years?

MannKind Corp stock has given -16.91% share price returns and 31.14% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?